ANTH (Anthera Pharmaceuticals) OCF Margin %: 0.00% (As of Mar. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Anthera Pharmaceuticals OCF Margin %?

Anthera Pharmaceuticals ANTH OCF Margin % is 0.00% as of Mar. 2018.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Anthera Pharmaceuticals's Cash Flow from Operations for the three months ended in Mar. 2018 was $-9.38 Mil. Anthera Pharmaceuticals's Revenue for the three months ended in Mar. 2018 was $0.00 Mil. Therefore, Anthera Pharmaceuticals's OCF Margin % for the quarter that ended in Mar. 2018 was 0.00%.

As of today, Anthera Pharmaceuticals's current OCF Yield % is -1,065,066.67%.

The historical rank and industry rank for Anthera Pharmaceuticals's OCF Margin % or its related term are showing as below:


ANTH's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -70.9
* Ranked among companies with meaningful OCF Margin % only.

Anthera Pharmaceuticals OCF Margin % Related Terms

Anthera Pharmaceuticals OCF Margin % Historical Data

* Premium members only.

The historical data trend for Anthera Pharmaceuticals's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anthera Pharmaceuticals OCF Margin % Chart

Anthera Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -970.39 -33,737.24 0.00

Anthera Pharmaceuticals Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Anthera Pharmaceuticals OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Anthera Pharmaceuticals's OCF Margin for the fiscal year that ended in Dec. 2017 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2017 )/Revenue (A: Dec. 2017 )
=-36.9/0
= %

Anthera Pharmaceuticals's OCF Margin for the quarter that ended in Mar. 2018 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2018 )/Revenue (Q: Mar. 2018 )
=-9.381/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Anthera Pharmaceuticals (ANTH) has a OCF Margin % of 0.00% as of Mar. 2018. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Anthera Pharmaceuticals and its competitors.
Is Anthera Pharmaceuticals' OCF Margin % too high?
Anthera Pharmaceuticals' current OCF Margin % is 0.00%.
How does Anthera Pharmaceuticals' OCF Margin % compare to TIKRF and CAPS?
Anthera Pharmaceuticals' OCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Anthera Pharmaceuticals and its competitors. Anthera Pharmaceuticals's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthera Pharmaceuticals stock overvalued right now?
Anthera Pharmaceuticals (ANTH) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Anthera Pharmaceuticals (ANTH), the current OCF Margin % is 0.00% as of Mar. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anthera Pharmaceuticals Business Description

Address 700 Milam, Suite 1300, Houston, TX, USA, 77002
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.